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Herpesvirus reactivation is common after liver transplantation.
Objective: Analyze the presence of cytomegalovirus (HCMV) and human herpesvirus-6 (HHV-
6)  DNA in liver donor biopsies, seeking to better understand issues involving human donor
leukocyte  antigens (HLA)-A, B and DR, as well as correlations with acute cellular rejection.
Methods: Fifty-nine liver transplantation patients were investigated for the presence of
HCMV and HHV-6 DNA in liver donor biopsies, using the Nested-PCR technique. The clinical
donor  information and HLA matches were obtained from the São Paulo State Transplant
System.  The recipients’ records regarding acute cellular rejection were studied.
Results: Seven (11.8%) biopsies were positive for HCMV DNA and 29 (49%) were  positive for
HHV-6 DNA. In 14 donors with HLA-DR 15 nine had HHV-6 DNA positive liver biopsy with a
tendency for signiﬁcant association (p = 0.09), 22 recipients developed acute cellular rejection
and  9/22 were positive for HLA-DR 15 (p = 0.03; 2 = 4.51), which was statistically signiﬁcant
in  univariate analysis and showed a tendency after multivariate analysis (p = 0.08).Conclusion:  HHV-6 DNA was prevalent in liver donors studied as well as HLA-DR 15. These
ﬁndings  suggest that patients with HLA-DR 15 in liver donor biopsies develop more  rejection
after  liver transplantation.
in  14–82% of solid organ transplantations. HCMV infection
13 EIn liver transplantation patients, cytomegalovirus (HCMV) and
human  herpesvirus-6 HHV-6 are the most common infec-
© 20tions.  These viruses undergo latency and reactivation episodes
in  the host. HCMV prevalence ranges from 20% to 60%.
Among  patients with active infections, 80% develop clinical
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may  vary depending on baseline HCMV-speciﬁc immunity
(donor and recipient seropositivity), the overall net state
of  immunosuppression. HCMV infection may  be the result
 de CC BY-NC-ND
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f reactivation or reinfection (in HCMV-seropositive recipi-
nts)  or primary infection (in a HCMV-seronegative recipient
ho  received an allograft from a HCMV-seropositive donor
D+/R−]).3
The role of human leukocyte antigen (HLA) between donor
nd  recipient in organ transplantation has been widely stud-
ed  and some authors suggest that HLA-A, B, or DR mismatch
ncreases the incidence of HCMV hepatitis in both primary and
econdary  HCMV infections and is associated with increased
raft  failure. HHV-6 reactivation and infections after liver
ransplantation are asymptomatic, although the risk factors
re  not completely deﬁned.4–6
The aim of the present study was  to analyze the presence
f  HCMV and HHV-6 DNA in liver donor biopsies, seeking to
etter  understand issues involving HLA-A, B, and DR donor, as
ell as associations with acute cellular rejection.
At the Clinical Hospital of the Sao Paulo State University in
ampinas  – Unicamp – in the period between January 2006 and
ecember  2008, 59 orthotopic liver transplants were carried
ut  at the Liver Transplant Unit. The patients were followed
p  and their donor liver biopsies were  used in this study.
The  liver biopsies were collected from the organ before
ransplantation at the bench (pre-transplant graft biopsy).
his  was  an observational, analytic, longitudinal prospective
ohort  study.
Children and retransplantation patients were excluded
rom  the study. A total of 59 patients enrolled met  the follow-
ng  inclusion criteria: 1 – sufﬁcient liver biopsy material for
NA  virus analysis by the N-PCR method; 2 – clinical donors’
nformation available from the State Transplant System, São
aulo, Brazil.
The  presence of HCMV and HHV-6 DNA N-PCR was  inves-
igated  as well as their co-infection in liver donor biopsies.
hese  analyses were  performed in formalin-ﬁxed parafﬁn-
mbedded material. Patients’ records were  analyzed in the
rst  six months post-transplant period to assess acute cellu-
ar  rejection. HLA matches were  obtained from the Sao Paulo
ransplant  system.
All  patients from this study had received prophylaxis for
erpes  simplex infection and standard immunosuppressive
herapy according to our protocol.7 All recipients had positive
gG  for HCMV before transplantation and there was no recipi-
nt  serology for HHV-6 before transplantation. All donors had
ositive  serology for HCMV and no HHV-6 serology results.
Diagnosis  and monitoring of graft acute cellular rejec-
ion  were  performed according to the Banff International
onsensus.8 All acute rejection episodes were treated with
ethilprednisolone according to our protocol.
Viral DNA was  extracted from liver biopsy specimens using
he  Qiagen Dneasy tissue kit (Uniscience, São Paulo, Brazil)
ccording  to the manufacturer’s instructions with some mod-
ﬁcations  to achieve ﬁnal elution volumes of 30 L.7
Five microliters of extracted DNA were  used for the N-
CR  for HCMV and HHV-6 using a mixture containing speciﬁc
rimers  (HCMV primers; Invitrogen, São Paulo, Brazil), using
 previously described technique9 with some modiﬁcations.
peciﬁc primers for HHV-6 (HHV-6 primers; Invitrogen) were
pplied  with a technique previously described by Secchiero
t  al.10 with some modiﬁcations. The ampliﬁcations were  per-
ormed  in a Peltier Thermal Cycler (MJ  Research, Waltham,4;1 8(2):220–224  221
MA,  USA). The N-PCR products were  analyzed under UV light
after  electrophoresis in agarose gel (Gibco-BRL Life Technol-
ogy,  Carlsbad, CA, USA) in tetramethylbenzidine buffer after
staining  with ethidium bromide. All primer sequences and
PCR  products were analyzed using the Genbank database
before  initiating the study. PCR using primers for beta-globin
gene  ampliﬁcation, which were performed on samples to
detect  possible false-negative results, were not included in this
study.7
Categorical variables were compared using Fisher’s exact
test  and multiple regression analysis was performed using
acute  cellular rejection as the dependent variable by Statsoft
11.0  program (NY, USA, 2012). p < 0.05 was considered statisti-
cally  signiﬁcant.
This  study was  approved by the Institutional Ethics Com-
mittee  of the Faculty of Medical Sciences, UNICAMP (CEP no.
030/2006).
Fifty-nine  liver donors were  studied, 36 (61%) were  men  and
23  (39%) were  women.
Thirty  (51%) donors were of blood group O, 22 (37%) blood
group  A, ﬁve blood group B, and two group AB. The mean
age  was  32.2 years ± 13.0. Thirty-one (52%) donors died due to
traumatic brain injury, 21 (35%) donors due to cerebrovascular
accident (CVA) and seven donors had other causes of death.
Twenty-nine (49%) out of 59 donors studied had a positive
serology for HHV-6 DNA and seven (11.8%) were  for HCMV-
DNA.  Liver donor biopsies had a co-infection (HCMV and HHV-
6)  positivity rate of 10% (6/59).
We also investigated HLA matches (A, B and DR locus)
between HCMV-DNA and HHV-6-DNA. These data are
described  in Table 1. Of the 14 (23.7%) donors with HLA-DR15,
nine  (64%) were positive for HHV-6 DNA at liver biopsy with
a  tendency for signiﬁcant association (p = 0.09; Fisher’s exact
test).  No association was  found between CMV  DNA  positivity
in  liver biopsies and HLA-DR 15.
After liver transplantation, 22 (37%) recipients developed
acute cellular rejection and 41% (9/22) had HLA-DR15 (p = 0.03;
2 = 4.51; Fisher’s exact test). Moreover, in multivariate anal-
ysis  presence of DR15 had a tendency to be associated with
acute  cellular rejection after transplantation (Table 2). Like-
wise,  HLA DR15 was  associated with HHV-6 positivity in donor
biopsies.
The  results of the present study indicate that HHV-6 DNA
and  HCMV DNA were commonly detected in donor liver trans-
plantation  at the Liver Transplant Unit – Unicamp, as shown
in  other studies we have previously carried out.11 HHV-6 and
HCMV  in patients are common after liver transplantation and
the  interaction of these viruses can increase their pathogenic
effects.12–14
In our study, HHV-6 DNA was  observed in 49% and HCMV
DNA  in 11.8% of donor liver biopsies. We could ﬁnd no pub-
lished  reports to conﬁrm these data but it is known that these
viruses  can have an incidence of over 80% (serologic status) in
the human population.15,16 This is an important fact because
herpesviruses can establish a latent infection for the lifetime
of  the host.17 A recent study identiﬁed high intrahepatic HHV-
6  viral load, suggesting that HHV-6 reactivation in the liver
18graft  is of clinical relevance.
In our results, of 23.7% (14/59) HLA-DR15 donors, nine 9
(64%)  had positive HHV-6 DNA at liver biopsy with a tendency
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Table 1 – Donor HLA information association with HHV-6 and CMV  DNA and acute cellular rejection in
post-transplantation period.
Donor case HLA Donor liver biopsies Post-tranplantation
A B DR HHV-6 DNA HCMV DNA ACR
1 2, 11 7, 27 1, 15 Positive Positive Positive
2 1, 2 8, 15 3, 15 Positive Negative Positive
3 26, 66 38, 5 11, 15 Negative Negative Positive
4 11, 23 44, 57 11, 15 Negative Negative Positive
5 2, 24 7, 57 7, 15 Positive Positive Positive
6 2, 3 42, 44 7, 15 Positive Negative Positive
7 24, 30 18,  35 11,  15 Positive Negative Positive
8  0, 2 40,  50 7,  15 Positive Negative Positive
9  24, 29 7, 44 7, 15 Negative Negative Positive
10 2, 11 35, 44 12, 14 Positive Negative Positive
11 31, 32 0, 4 4, 11 Positive Negative Positive
12 2, 26 15, 46 4, 13 Negative Negative Positive
13 1, 68 78, 55 1, 13 Negative Negative Positive
14 2, 32 39, 51 1, 4 Negative Negative Positive
15 0, 2 5, 9 4, 6 Negative Negative Positive
16 0, 8 2, 4 8, 1 Negative Negative Positive
17 2, 0 44, 39 11, 16 Negative Negative Positive
18 69, 35 0, 0 0, 0 Positive Negative Positive
19 3, 32 35, 0 8, 13 Negative Negative Positive
20 3, 0 15, 40 8, 11 Positive Negative Positive
21 2, 68 40, 57 4, 7 Negative Negative Positive
22 3, 11 35, 51 3, 11 Positive Negative Positive
23 3, 32 15, 35 1, 11 Positive Negative Negative
24 24, 32 35,  44 11,  15 Negative  Negative Negative
25 3, 24 35, 44 7, 0 Negative Negative Negative
26 1, 3 7, 49 0, 13 Positive Negative Negative
27 31, 66 18, 58 12, 15 Negative Negative Negative
28 2, 29 15, 39 9, 13 Negative Negative Negative
29 1, 2 35, 51 13, 14 Positive Negative Negative
30 2, 31 44, 51 8, 16 Negative Negative Negative
31 5, 1 5, 4 8, 2 Positive Negative Negative
32 0, 2 44, 49 1, 7 Negative Negative Negative
33 11, 24 35, 37 3, 10 Negative Negative Negative
34 3, 1 2, 5 4, 8 Negative Negative Negative
35 2, 34 39, 56 1, 13 Negative Negative Negative
36 1, 2 18, 50 7, 11 Negative Negative Negative
37 24, 0 8, 51 3, 15 Positive Negative Negative
38 2, 3 35, 57 7, 8 Negative Negative Negative
39 29, 0 15, 0 10, 0 Negative Positive Negative
40 1, 2 8, 14 3, 7 Positive Positive Negative
41 3, 30 35, 53 11, 14 Positive Negative Negative
42 2, 30 44, 49 12, 13 Negative Negative Negative
43 1, 24 8, 14 1, 3 Positive Negative Negative
44 2, 31 15, 38 13, 16 Positive Negative Negative
45 26, 30 38, 58 11, 13 Negative Negative Negative
46 30, 68 14, 18 1, 3 Positive Positive Negative
47 3, 24 7, 8 13, 15 Positive Positive Negative
48 30, 33 14, 0 3, 15 Positive Positive Negative
49 2, 33 53, 0 3, 8 Negative Negative Negative
50 1, 30 8, 0 3, 13 Negative Negative Negative
51 2, 3 15, 35 3, 0 Positive Negative Negative
52 1, 23 15, 8 15, 0 Negative Negative Negative
53 2, 29 44, 50 7, 11 Negative Negative Negative
54 24, 0 40, 0 1, 3 Positive Negative Negative
55 2, 3 51, 57 1, 4 Positive Negative Negative
56 26, 68 27, 4 4, 13 Positive Negative Negative
57 11, 31 51, 56 1, 13 Positive Negative Negative
58 1, 2 8, 2 13, 0 Positive Negative Negative
59 1, 29 7, 44 1, 4 Negative Negative Negative
HLA, human leukocyte antigens; HCMV, cytomegalovirus; HHV-6, human herpesvirus-6; ACR, acute cellular rejection.
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Table 2 – Multivariate regression analysis and clinical variables using ACR as dependent variable.
Regression summary for dependent variable: ACR R (HLA DR × ACR), R = 0.39122164, R2 = 0.15305437, Adjusted R2 = –, F(13,45) = 0.62555
b* SE of b* b SE of b t(45) p-Value
Intercept 89.87960 34.51059 2.60441 0.012427
ICU donor −0.026915 0.156357 −0.00393 0.02286 −0.17214 0.864100
BDC donor 0.040342 0.154217 0.01144 0.04372 0.26159 0.794831
Gender donor 0.073123 0.154645 0.07156 0.15133 0.47284 0.638611
Age donor −0.133910 0.165004 −0.00487 0.00600 −0.81156 0.421319
BMI donor 0.089542 0.174625 0.01308 0.02551 0.51277 0.610622
Cold ischemia (min) 0.010176 0.149089 0.00002 0.00034 0.06825 0.945887
Warm ischemia (min) −0.195094 0.163400 −0.00396 0.00331 −1.19397 0.238747
HCMV DNA donor −0.133295 0.184690 −0.19933 0.27619 −0.72172 0.474198
HHV-6 DNA donor −0.019943 0.156192 −0.01929 0.15108 −0.12768 0.898969
HLA DR 15 donor 0.300259 0.168916 0.33345 0.18759 1.77756 0.082234
Ender recipient −0.075116 0.152701 −0.07774 0.15803 −0.49192 0.625171
Age recipient 0.199200 0.168171 0.00763 0.00644 1.18451 0.242431
BMI recipient 0.053993 0.156713 0.00602 0.01748 0.34453 0.732052
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cytomegalovirus; HHV-6, human herpesvirus-6; BMI, body mass inde
o have signiﬁcant association. No association was  found
etween  CMV  DNA positivity in liver biopsies and HLA-DR15
resence.
Some  studies have suggested that HLA compatibility can
ave  clinical signiﬁcance after liver transplantation.4,5 Manez
t  al. suggest that an HLA-DR mismatch between donor
nd  recipient increases the incidence of HCMV hepatitis and
nfections.4 Another study examined the incidence of HCMV
iremia  after liver transplantation with the HLA matching
nﬂuence, and found no association.19
Some patients in this study developed graft rejection asso-
iated  with HLA-DR15. An a recent study we showed that
1%  of the recipients developed graft rejection.11 Acute or
hronic  rejection remains the most common reason for graft
ailure,  especially for patients who have HLA mismatching.6
he role of HLA matching between donor and recipient in
rgan  transplant rejection has been pointed out in some stud-
es  and a degree of HLA mismatching could be associated
ith increased graft failure.6,20 Menez et al. showed that HLA-
R  mismatching may  accelerate chronic rejection of liver
ransplants.4
In summary HHV-6 DNA was  prevalent in liver donors stud-
ed  as well as HLA-DR15. These ﬁndings suggest that detection
f  HLA-DR15 in liver donor biopsies developed more  rejection
fter  liver transplantation. However, further studies are neces-
ary  to clarify these data, especially HHV-6 infection in donor
amples  together with HLA mismatches.
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